Ask AI

Could It Be MASH? Early Detection and Intervention to Improve Metabolic Outcomes

Gain in-depth knowledge on metabolic dysfunction–associated steatotic liver disease (MASLD) or metabolic dysfunction–associate steatohepatitis (MASH) as well as expert-informed strategies to screen for, risk stratify, and implement the latest treatment guidance and emerging therapies based on current evidence, through expert-written ClinicalThought commentaries, downloadable slides, and an on-demand webcast.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Novo Nordisk.

Boehringer Ingelheim Pharmaceuticals, Inc.

Novo Nordisk